Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News provided by
Share this article
Share this article
BRIDGEWATER, N.J., March 5, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed s Compensation Committee and made as a material inducement to each employee s entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on March 1, 2021 to purchase an aggregate 27,770 shares of Insmed common stock at an exercise price of $37.73 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration
PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘
Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (“PharmaEngine”) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012.
As previously disclosed in the Nanobiotix prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020, in November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. In a letter dated December 1, 2020, PharmaEngine responded to the Company’s notification of material breach, denying a material breach of the Licens
PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) March 4, 2021 Regulatory News: NANOBIOTIX (Euronext : NANO NASDAQ: NBTX - the
Company ), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. ( PharmaEngine ) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012. As previously disclosed in the Nanobiotix prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020, in November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. In a letter dated December 1, 2020, PharmaEngine responded to the Company s notification of material breach, denying a material breach of the License and Collaboration agreement, and asserting certain material brea
Score Media and Gaming (TSX:SCR)(NASDAQ:SCR) shares have soared by more than 550% in the past six months. theScore stock is a buy for its strong growth.
DBV Technologies S.A.: DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference
DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021.
A webcast of the presentation at the H.C. Wainwright Healthcare Conference will be available on the Investors & Media section of the Company s website beginning Tuesday, March 9
th at 7:00 a.m. ET: